Illustration: Aïda Amer/Axios
InfuCare, a One Equity-backed infusion provider, is exploring a sale through JPMorgan, three sources familiar with the situation tell Axios Pro.
Why it matters: The process comes as President Trump's "most favored nation" drug pricing plan casts a chill over the red-hot infusion market.
